1. Medtech Insight
  2. >>Geography
  3. >>Europe

Thoratec Takes Steps Into PCI-Support Market With EU Roll-Out Of HeartMate PHP

The company plans a targeted roll-out of its heart pump in select European markets following a CE mark for the device, indicated to help stabilize patients during high-risk percutaneous coronary interventions.

Thoratec Corp. will make its first push into the short-term percutaneous coronary intervention circulatory support market as it performs a roll-out of its HeartMate PHP (Percutaneous Heart Pump) device in select European markets during the next two years.

While Thoratec is a leader in the left-ventricular assist device space for heart failure patients on the transplant list or in need of long-term support, Abiomed Inc. is ahead in the catheter pump market to help stabilize patients during high-risk PCIs with the March FDA approval of its Impella 2.5 device. Some analysts have projected that the U.S. market for these types of devices may be worth $3 billion annually

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

More from Geography

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.